UK biotech firms extend rush to US stock market

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

UK biotech firms extend rush to US stock market

Biotech_Adobe_575x375_Oct21
Female scientist researching samples in laboratory | Stevica Mrdja/Microgen - stock.adobe.com

Huge demand for exposure to biotech companies among US equity investors is continuing to drive UK firms to list on the other side of the Atlantic through an IPO on the Nasdaq. On Thursday, Immunocore, a late-stage biotech firm focused on T-cell technology, priced an enlarged offering on the exchange and, on Friday, UK healthcare investor Syncona announced it was exploring a US IPO for one of its portfolio companies.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article